Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

eFFECTOR Therapeutics Q1 2024 GAAP EPS $(2.16) Beats $(2.17) Estimate; Reports Cash Runway Into Q1 Of 2025

Author: Benzinga Newsdesk | May 09, 2024 04:51pm
eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(2.16) per share which beat the analyst consensus estimate of $(2.17) by 0.46 percent.

Posted In: EFTR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist